Cargando…

Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX

Two patients underwent hemodialysis. Case 1 with stage IV gastric cancer was treated with reduced doses of capecitabine (1,000 mg/m(2)/day, days 1 to 14) and oxaliplatin (65 mg/m(2), day 1). Although grade 1 thrombocytopenia occurred in the first cycle, grade 3 thrombocytopenia developed in the seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Kenta, Zhou, Qiliang, Matsumoto, Yoshifumi, Saiki, Takuro, Moriyama, Masato, Saijo, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815905/ https://www.ncbi.nlm.nih.gov/pubmed/31243213 http://dx.doi.org/10.2169/internalmedicine.2718-19

Ejemplares similares

Treatments and outcomes of older patients with esophageal cancer: Comparison with younger patients
por: Matsumoto, Yoshifumi, et al.
Publicado: (2019)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

Efficacy of Aidi Injection and Brucea javanica Oil Emulsion Injection in Rectal Cancer during CapeOX Adjuvant Chemotherapy
por: Meng, Wenjun, et al.
Publicado: (2021)

Termination of Palliative Chemotherapy Near the End of Life: A Retrospective Study of Gastrointestinal Cancer Patients
por: Matsumoto, Yoshifumi, et al.
Publicado: (2023)

Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis
por: Hirata, Fumihiro, et al.
Publicado: (2018)

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
por: Fei, Zuo, et al.
Publicado: (2019)

Cancers among adolescents and young adults at one institution in Japan
por: Kamimura, Kensuke, et al.
Publicado: (2018)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial
por: Liu, Fangqi, et al.
Publicado: (2019)

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)
por: Matsuoka, Hiroshi, et al.
Publicado: (2020)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
por: Nakayama, Goro, et al.
Publicado: (2017)

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
por: Fang, Xuefeng, et al.
Publicado: (2023)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy
por: Xiao, Ai Tang, et al.
Publicado: (2020)

Analysis of Pharmacokinetics in the Cochlea of the Inner Ear
por: Sawamura, Seishiro, et al.
Publicado: (2021)

A strategy for low-cost portable monitoring of plasma drug concentrations using a sustainable boron-doped-diamond chip
por: Saiki, Takuro, et al.
Publicado: (2023)

Editorial for the series on gastric and gastroesophageal cancer treatment in 2020
por: Almhanna, Khaldoun
Publicado: (2020)

Gastric Anisakiasis Masquerading as Gastroesophageal Reflux Disease
por: Groudan, Kevin, et al.
Publicado: (2023)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction
por: Ko, Seung Yeon, et al.
Publicado: (2014)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease
por: Sugihartono, Titong, et al.
Publicado: (2022)

Adequacy of Hemodialysis Serves as an Independent Predictor of Humoral Response to ChAdOx1 Prime-Boost Vaccination in Hemodialysis Patients
por: Chen, Chun-Yu, et al.
Publicado: (2022)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
por: Gronnier, Caroline
Publicado: (2022)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Influence of gastric morphology on gastroesophageal reflux in adults: An observational study
por: Cheng, She-Meng, et al.
Publicado: (2021)

Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy
por: Badgwell, Brian, et al.
Publicado: (2017)

Narrative review of the role of gastroenterologist in the diagnosis, treatment and palliation in gastric and gastroesophageal cancer
por: Diaz, Liege I., et al.
Publicado: (2020)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
por: He, Jinjie, et al.
Publicado: (2023)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

The Characteristics of Postprandial Proximal Gastric Acid Pocket in Gastroesophageal Reflux Disease
por: Wu, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c5hgsf1juc4k4eosajqm87mgq5